Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

349 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation.
Gai D, Chen JR, Stewart JP, Nookaew I, Habelhah H, Ashby C, Sun F, Cheng Y, Li C, Xu H, Peng B, Garg TK, Schinke C, Thanendrarajan S, Zangari M, Chen F, Barlogie B, van Rhee F, Tricot G, Shaughnessy JD Jr, Zhan F. Gai D, et al. Among authors: ashby c. J Clin Invest. 2022 Sep 15;132(18):e159527. doi: 10.1172/JCI159527. J Clin Invest. 2022. PMID: 35881476 Free PMC article.
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.
Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, Tytarenko R, Bauer MA, Meissner T, Deshpande S, Patel PH, Buzder T, Molnar G, Peterson EA, van Rhee F, Zangari M, Thanendrarajan S, Schinke C, Tian E, Epstein J, Barlogie B, Davies FE, Heuck CJ, Walker BA, Morgan GJ. Weinhold N, et al. Among authors: ashby c. Blood. 2016 Sep 29;128(13):1735-44. doi: 10.1182/blood-2016-06-723007. Epub 2016 Aug 11. Blood. 2016. PMID: 27516441 Free PMC article.
Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.
Chavan SS, He J, Tytarenko R, Deshpande S, Patel P, Bailey M, Stein CK, Stephens O, Weinhold N, Petty N, Steward D, Rasche L, Bauer M, Ashby C, Peterson E, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Barlogie B, Mughal TI, Davies FE, Morgan GJ, Walker BA. Chavan SS, et al. Among authors: ashby c. Blood Cancer J. 2017 Feb 24;7(2):e535. doi: 10.1038/bcj.2017.12. Blood Cancer J. 2017. PMID: 28234347 Free PMC article.
The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma.
Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, Zangari M, Rasche L, Weinhold N, Alapat D, Bellamy W, Ashby C, Mattox S, Epstein J, Yaccoby S, Barlogie B, Hoering A, Bauer M, Walker BA, Davies FE, Morgan GJ. Thanendrarajan S, et al. Among authors: ashby c. Haematologica. 2017 Sep;102(9):e364-e367. doi: 10.3324/haematol.2017.168872. Epub 2017 May 26. Haematologica. 2017. PMID: 28550191 Free PMC article. No abstract available.
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.
Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, Bauer M, Stein C, Deshpande S, Wardell C, Buzder T, Molnar G, Zangari M, van Rhee F, Thanendrarajan S, Schinke C, Epstein J, Davies FE, Walker BA, Meissner T, Barlogie B, Morgan GJ, Weinhold N. Rasche L, et al. Among authors: ashby c. Nat Commun. 2017 Aug 16;8(1):268. doi: 10.1038/s41467-017-00296-y. Nat Commun. 2017. PMID: 28814763 Free PMC article.
The genomic landscape of plasma cells in systemic light chain amyloidosis.
Boyle EM, Ashby C, Wardell CP, Rowczenio D, Sachchithanantham S, Wang Y, Johnson SK, Bauer MA, Weinhold N, Kaiser MF, Johnson DC, Jones JR, Pawlyn C, Proszek P, Schinke C, Facon T, Dumontet C, Davies FE, Morgan GJ, Walker BA, Wechalekar AD. Boyle EM, et al. Among authors: ashby c. Blood. 2018 Dec 27;132(26):2775-2777. doi: 10.1182/blood-2018-08-872226. Epub 2018 Nov 16. Blood. 2018. PMID: 30446495 Free article. No abstract available.
Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.
Rasche L, Alapat D, Kumar M, Gershner G, McDonald J, Wardell CP, Samant R, Van Hemert R, Epstein J, Williams AF, Thanendrarajan S, Schinke C, Bauer M, Ashby C, Tytarenko RG, van Rhee F, Walker BA, Zangari M, Barlogie B, Davies FE, Morgan GJ, Weinhold N. Rasche L, et al. Among authors: ashby c. Leukemia. 2019 Jul;33(7):1713-1722. doi: 10.1038/s41375-018-0329-0. Epub 2018 Dec 20. Leukemia. 2019. PMID: 30573775 Free PMC article.
BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma.
Boyle EM, Ashby C, Tytarenko RG, Deshpande S, Wang H, Wang Y, Rosenthal A, Sawyer J, Tian E, Flynt E, Hoering A, Johnson SK, Rutherford MW, Wardell CP, Bauer MA, Dumontet C, Facon T, Thanendrarajan S, Schinke CD, Zangari M, van Rhee F, Barlogie B, Cairns D, Jackson G, Thakurta A, Davies FE, Morgan GJ, Walker BA. Boyle EM, et al. Among authors: ashby c. Clin Cancer Res. 2020 May 15;26(10):2422-2432. doi: 10.1158/1078-0432.CCR-19-1507. Epub 2020 Jan 27. Clin Cancer Res. 2020. PMID: 31988198 Free article.
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns.
Schinke C, Boyle EM, Ashby C, Wang Y, Lyzogubov V, Wardell C, Qu P, Hoering A, Deshpande S, Ryan K, Thanendrarajan S, Mohan M, Yarlagadda N, Khan M, Choudhury SR, Zangari M, van Rhee F, Davies F, Barlogie B, Morgan G, Walker BA. Schinke C, et al. Among authors: ashby c. Blood Cancer J. 2020 Jun 19;10(6):70. doi: 10.1038/s41408-020-0336-z. Blood Cancer J. 2020. PMID: 32555163 Free PMC article.
349 results